CureVac Statistics
Total Valuation
CureVac has a market cap or net worth of $624.71 million. The enterprise value is $447.31 million.
Important Dates
The next estimated earnings date is Thursday, May 22, 2025, before market open.
| Earnings Date | May 22, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
CureVac has 224.31 million shares outstanding. The number of shares has increased by 9.65% in one year.
| Current Share Class | 224.31M |
| Shares Outstanding | 224.31M |
| Shares Change (YoY) | +9.65% |
| Shares Change (QoQ) | +0.01% |
| Owned by Insiders (%) | 6.24% |
| Owned by Institutions (%) | 17.02% |
| Float | 123.54M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 9.47 |
| Forward PS | n/a |
| PB Ratio | 1.66 |
| P/TBV Ratio | 1.66 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 6.34 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 2.29, with a Debt / Equity ratio of 0.10.
| Current Ratio | 2.29 |
| Quick Ratio | 2.19 |
| Debt / Equity | 0.10 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -54.30% and return on invested capital (ROIC) is -32.31%.
| Return on Equity (ROE) | -54.30% |
| Return on Assets (ROA) | -24.52% |
| Return on Invested Capital (ROIC) | -32.31% |
| Return on Capital Employed (ROCE) | -63.93% |
| Revenue Per Employee | $60,210 |
| Profits Per Employee | -$254,547 |
| Employee Count | 1,172 |
| Asset Turnover | 0.09 |
| Inventory Turnover | 13.43 |
Taxes
In the past 12 months, CureVac has paid $2.29 million in taxes.
| Income Tax | 2.29M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -8.75% in the last 52 weeks. The beta is 2.53, so CureVac's price volatility has been higher than the market average.
| Beta (5Y) | 2.53 |
| 52-Week Price Change | -8.75% |
| 50-Day Moving Average | 3.36 |
| 200-Day Moving Average | 3.23 |
| Relative Strength Index (RSI) | 38.10 |
| Average Volume (20 Days) | 620,799 |
Short Selling Information
The latest short interest is 4.06 million, so 1.81% of the outstanding shares have been sold short.
| Short Interest | 4.06M |
| Short Previous Month | 3.91M |
| Short % of Shares Out | 1.81% |
| Short % of Float | 3.29% |
| Short Ratio (days to cover) | 6.42 |
Income Statement
In the last 12 months, CureVac had revenue of $70.57 million and -$298.33 million in losses. Loss per share was -$1.33.
| Revenue | 70.57M |
| Gross Profit | -92.44M |
| Operating Income | -306.05M |
| Pretax Income | -297.84M |
| Net Income | -298.33M |
| EBITDA | -289.66M |
| EBIT | -306.05M |
| Loss Per Share | -$1.33 |
Full Income StatementBalance Sheet
The company has $216.99 million in cash and $41.82 million in debt, giving a net cash position of $175.16 million or $0.78 per share.
| Cash & Cash Equivalents | 216.99M |
| Total Debt | 41.82M |
| Net Cash | 175.16M |
| Net Cash Per Share | $0.78 |
| Equity (Book Value) | 403.44M |
| Book Value Per Share | 1.80 |
| Working Capital | 151.69M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$310.57 million and capital expenditures -$35.99 million, giving a free cash flow of -$349.62 million.
| Operating Cash Flow | -310.57M |
| Capital Expenditures | -35.99M |
| Free Cash Flow | -349.62M |
| FCF Per Share | -$1.56 |
Full Cash Flow StatementMargins
| Gross Margin | -131.00% |
| Operating Margin | -433.71% |
| Pretax Margin | -419.52% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
CureVac does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -9.65% |
| Shareholder Yield | -9.65% |
| Earnings Yield | -47.93% |
| FCF Yield | -56.17% |
Dividend DetailsAnalyst Forecast
The average price target for CureVac is $10.00, which is 259.07% higher than the current price. The consensus rating is "Hold".
| Price Target | $10.00 |
| Price Target Difference | 259.07% |
| Analyst Consensus | Hold |
| Analyst Count | 3 |
| Revenue Growth Forecast (5Y) | 29.08% |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsStock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
CureVac has an Altman Z-Score of -1.94 and a Piotroski F-Score of 2. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -1.94 |
| Piotroski F-Score | 2 |